{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"deadweight_loss_reduction__pharmacology_toxicology","archetype_slug":"deadweight_loss_reduction","domain_slug":"pharmacology_toxicology","title":"Risk-tiered review of non-risk-increasing toxicology protocol amendments","opportunity_summary":"The candidate proposes an expedited, overrideable review lane for a predefined subset of non-risk-increasing toxicology protocol amendments. It could reduce procedural waiting, idle study capacity, and animal holding time while reserving full review for hazardous or uncertain changes. The opportunity remains hypothetical because the packet contains no amendment-level evidence that avoidable review delay is material or that the proposed eligibility screen reliably preserves welfare, biosafety, validity, and compliance protections.","adopter_authorizer":"A research institution or toxicology facility, acting through its formally designated animal-use, biosafety, scientific, and compliance authorities, which retain approval, classification, override, suspension, and rollback powers.","scores":{"meaningful_impact":{"score":3,"rationale":"Reducing study delays and unnecessary animal holding could materially benefit animals, staff, facilities, sponsors, and downstream evidence users, but the packet provides no evidence about the frequency, duration, or attributable burden of the hypothesized delay."},"stakeholder_pull":{"score":2,"rationale":"The proposal names affected investigators, staff, reviewers, institutions, sponsors, animals, and evidence users, but supplies no observed complaints, adoption requests, queue data, or other affirmative evidence of stakeholder demand."},"incremental_advantage":{"score":3,"rationale":"Unlike adding reviewer capacity or a portal, risk-tiered routing directly removes review intensity from predefined low-risk cases and is therefore meaningfully testable; however, its advantage disappears if necessary scientific consultation or general capacity scarcity, rather than routing, causes the delay."},"distinctiveness_plausibility":{"score":2,"rationale":"The combination of predefined eligibility, accountable expedited review, override, exclusions, monitoring, and rollback is coherent, but prior art is explicitly unsearched, so distinctiveness relative to existing delegated or expedited amendment practices cannot be credited."},"technical_implementability":{"score":4,"rationale":"A one-facility workflow using classification criteria, reviewer override, ordinary records, and outcome monitoring appears operationally feasible without new scientific technology. Reliability of classification and access to linked amendment and outcome data remain unproven."},"adoption_authority_feasibility":{"score":3,"rationale":"The packet identifies institutional authorities capable of approving, overriding, suspending, and rolling back the process, but governing requirements may prohibit abbreviated review and coordination across animal-use, biosafety, scientific, and compliance authorities may be substantial."},"evidence_readiness":{"score":4,"rationale":"The candidate specifies observable pathway metrics, a comparable baseline, separate problem and intervention falsifiers, safety outcomes, exclusions, and rollback conditions. Readiness is reduced because no pathway data, validated risk screen, case counts, or noninferiority thresholds are supplied."},"safety_net_benefit":{"score":4,"rationale":"If protection-equivalent, the approach could reduce animal holding time and redirect scarce reviewer attention toward hazardous changes. Explicit exclusions, accountable review, override, suspension, and rollback provide safeguards, although rare harms and misclassification may not be detected in a small pilot."},"scalability":{"score":3,"rationale":"The workflow concept could be replicated across facilities using standardized eligibility and monitoring, but legal requirements, amendment mixes, institutional authority structures, data systems, and classification performance may vary materially."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A bounded, nonbinding one-facility prospective pathway audit plus retrospective application of the proposed eligibility screen to completed amendments, including data linkage, manual classification, timing decomposition, safety and compliance outcome review, and comparison with ordinary full-review cases.","confidence":"LOW","assumptions":["Existing amendment, review, study-delay, animal-holding, deviation, welfare, biosafety, validity, and compliance records are accessible and linkable.","The assessment covers one facility and a limited historical and prospective case window.","Work requires investigator, reviewer, animal-care, compliance, data-analysis, and governance labor but no major equipment purchase.","Case volume and record quality are unspecified."]},"initial_deployment_startup":{"band_2026_usd":"50K_TO_250K","scope":"Design and authorization of a one-facility pilot, including eligibility rules, exclusions, reviewer override procedures, stopping limits, legal and compliance review, workflow configuration, staff training, data collection, and rollback preparation.","confidence":"LOW","assumptions":["Existing review and records systems can be configured rather than replaced.","The institution permits a formally approved expedited lane.","The pilot covers only a small predefined amendment set.","No material facility or laboratory modification is required."]},"operational_launch":{"band_2026_usd":"50K_TO_250K","scope":"Operation and evaluation of a bounded one-facility pilot with accountable expedited review, contemporaneous comparable baseline cases, monitoring of cycle time and protection outcomes, eligibility audits, and authority oversight.","confidence":"LOW","assumptions":["Launch is limited in duration and case volume.","Some duplicate or shadow review may be needed initially to assess classification reliability.","Rare-event safety assurance is not claimed from the bounded pilot.","Costs include reviewer, investigator, animal-care, compliance, analyst, and coordination labor."]},"annual_recurring":{"band_2026_usd":"50K_TO_250K","scope":"Ongoing operation at one facility, including expedited case review, periodic eligibility audits, outcome surveillance, refresher training, policy maintenance, reporting, and investigation of overrides or adverse signals.","confidence":"LOW","assumptions":["The process remains confined to one facility with moderate amendment volume.","Existing institutional systems remain usable.","Recurring costs exclude major litigation, system replacement, or expansion to multiple institutions.","Monitoring remains sufficiently intensive to protect welfare, biosafety, scientific validity, and compliance."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"UNCERTAIN","reason":"The hypothesized queueing and animal-holding problem is intelligible and measurable, but the sealed candidate supplies no observed amendment-level evidence that minor cases face material avoidable delay or attributable resource and animal-holding burdens."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"The institution operating the toxicology program is the adopter, and its formally designated animal-use, biosafety, scientific, and compliance authorities are explicitly assigned approval, classification, override, suspension, and rollback powers."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The candidate claims that predefined expedited routing will reduce cycle time and burden relative to comparable ordinary full-review cases without breaching prespecified protection limits; this differs testably from adding capacity or a portal while retaining full review."},"bounded_next_evidence_step":{"status":"YES","reason":"A nonbinding one-facility pathway audit can compare proposed-eligible amendments with comparable full-review cases, separate substantive consultation from routing delay, and falsify the problem before any live workflow change."},"no_unresolved_safety_or_authority_stop":{"status":"UNCERTAIN","reason":"The proposal includes cautious exclusions, accountable review, override, monitoring, suspension, and rollback, but screen sensitivity is unvalidated and the packet states that institutional authority or legal requirements may forbid abbreviated review."},"implementation_cost_scope_and_range":{"status":"YES","reason":"The candidate bounds initial use to one facility and a small predefined amendment set, permitting broad resource-equivalent ranges for audit, setup, launch, and recurring operation, although case volume and system requirements make confidence low."}},"blocking_evidence":["Amendment-level evidence showing whether proposed-eligible cases experience material avoidable submission-to-decision delay, duplicate work, study delay, or animal holding attributable to the review pathway.","A decomposition of elapsed time distinguishing necessary scientific consultation from routing, queueing, duplicate requests, reviewer scarcity, and other causes.","Retrospective evidence on the proposed screen's misclassification rate, overrides, later full-review reclassification, deviations, welfare events, biosafety events, scientific-validity consequences, and compliance outcomes.","Confirmation from the relevant institutional authorities that an expedited lane is legally and procedurally permissible.","Prior-art evidence establishing whether comparable expedited or delegated amendment-review practices already exist and what, if anything, is incrementally distinct."],"next_evidence_step":"At one facility, conduct a time-bounded nonbinding prospective audit of consecutive protocol amendments and retrospectively apply the proposed eligibility screen to completed cases. Compare proposed-eligible cases with comparable ordinary full-review cases on submission-to-decision time, reviewer touches, duplicate requests, substantive consultation time, study-days delayed, animal holding-days, deviations, overrides, reclassification, and protection outcomes. Falsify the problem if eligible cases show negligible avoidable delay or burden, or if proposed tiers have equivalent substantive-risk distributions; do not alter live review routing during this step.","research_questions":["What proportion of amendments satisfies the predefined non-risk-increasing criteria, and how consistently do independent authorized reviewers classify them?","How much elapsed time for proposed-eligible amendments is avoidable routing or queue time rather than necessary scientific consultation?","Are review delays causally associated with study idle time, animal holding-days, repeat work, or delayed dose-response evidence?","How often would the proposed screen miss changes affecting exposure, invasiveness, welfare, biosafety, scientific validity, or compliance?","What override, deviation, adverse-event, and later-reclassification rates would justify or reject a pilot?","Do governing rules and institutional policies permit accountable expedited review for the proposed amendment classes?","What expedited, delegated, or tiered amendment-review practices already exist, and is the proposed operational design or evaluation claim distinct?","Can a bounded evaluation define credible noninferiority limits despite rare welfare or biosafety harms and likely selection effects?","Would expedited routing reduce total reviewer workload or merely move work to intake, audit, or monitoring?","How sensitive are expected resource requirements to amendment volume, record quality, system configuration, and cross-authority coordination?"] ,"recommendation":"VALIDATE_PROBLEM_FIRST","uncertainty_constraints":["The existence, prevalence, and magnitude of the proposed review wedge are unverified.","No realized impact, stakeholder demand, amendment volume, or market size may be inferred from the packet.","Prior art and world novelty are unmeasured.","Risk-tier sensitivity, reviewer agreement, and override performance are unknown.","A small pilot may be unable to exclude rare but serious welfare, biosafety, validity, or compliance harms.","Legal and institutional permission for abbreviated review is unresolved.","Cost bands are resource-equivalent planning ranges, not estimates based on observed staffing, case volume, data quality, or system requirements."],"closed_book_prior_art_boundary":"Prior art is explicitly unsearched. This assessment assigns no novelty credit beyond the proposal's internally specified combination of risk-tiered intake, exclusions, accountable review, override, monitoring, and rollback, and makes no claim about whether institutions already use or have evaluated comparable expedited or delegated amendment-review practices."}